First patient with advanced breast cancer receives first dose in clinical trial of GlycoMimetics’ GMI-1359

This article was originally published here

The dose-escalating study will enroll up to 12 individuals with metastatic, hormone receptor positive breast cancer with stable or minimally progressive disease, including bone metastasis. GMI-1359 is a

The post First patient with advanced breast cancer receives first dose in clinical trial of GlycoMimetics’ GMI-1359 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply